SpO2 Validation Study - Philips FAST 2024 (FAST 2024)

Validation study to compare the accuracy of non-invasive Philips SpO2 sensors in detecting blood oxygen levels compared to invasive methods requiring a blood draw and lab analysis.

Study Overview

• Status: Completed
• Conditions: Pulse Oximetry
• Intervention / Treatment: Device: No Intervention

Detailed Description

To validate the SpO2 accuracy of the SpO2 sensors under test with the Philips FAST Pulse Oximetry technology during non-motion conditions over the range of 70-100% SaO2, when compared with the reference SaO2 obtained from CO-Oximetry analysis of arterial blood samples.

• Study Type: Observational
• Enrollment (Actual): 113

Contacts and Locations

Study Locations

• United States
  • Colorado
    • Louisville, Colorado, United States, 80027
      • Element Materials Technology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

The study population for this protocol will include a minimum of 96 to a maximum of 120 healthy, competent adult male and female participants of any race and ranging in pigmentation from light to dark. Participants will be non-smoking (or have refrained from smoking for 2 days) and between the ages of 18-50 years old.

Description

Inclusion Criteria:

• Participant must have the ability to understand and provide written informed consent
• Participant is adult between 18-50 years of age
• Participant must be willing and able to comply with study procedures and duration
• Participant is a non-smoker or who has not smoked within 2 days prior to the study.

Exclusion Criteria:

• Participant is considered as being morbidly obese (defined as BMI >39.5)
• Participants with compromised circulation (i.e., Raynaud's Syndrome), injury, or physical malformation of fingers, toes, hands, ears, nose, forehead/skull, or other sensor sites which would limit the ability to test sites needed for the study. Tattoo (e.g. permanent, Henna) or artificial dyes (including spray tan, pigmented tanning lotion) in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the particular sites utilized.)
• Females who are pregnant, who are trying to get pregnant, (confirmed by positive urine pregnancy test unless the participant is known to be not of child-bearing potential)
• Participants who have smoked in the last 2 days or participants who have refrained, for at least 48 hours, with COHb levels >3% as assessed with a Masimo Radical 7 (Rainbow)

• Participants with known respiratory conditions such as: (self-reported)

  • uncontrolled / severe asthma,
  • flu,
  • pneumonia / bronchitis,
  • shortness of breath / respiratory distress,
  • unresolved respiratory or lung surgery,
  • emphysema, COPD, lung disease,
  • Recent COVID (last 2 months)

• Participants with self-reported heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review)

  • high blood pressure: systolic >140 mmHg or diastolic >90 mmHg on 3 consecutive readings (reviewed during health screen),
  • have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA),
  • chest pain (angina),
  • heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen),
  • previous heart attack,
  • blocked artery,
  • unexplained shortness of breath,
  • congestive heart failure (CHF),
  • history of stroke,
  • transient ischemic attack,
  • carotid artery disease,
  • myocardial ischemia,
  • myocardial infarction,
  • cardiomyopathy,
  • implantable active medical device such as pacemaker or automatic defibrillator

• Participants with self-reported health conditions as identified in the Health Assessment Form

  • diabetes,
  • uncontrolled thyroid disease,
  • kidney disease / chronic renal impairment,
  • history of seizures (except childhood febrile seizures),
  • epilepsy,
  • history of unexplained syncope,
  • recent history of frequent migraine headaches,
  • recent symptomatic head injury (within the last 2 months),
  • Cancer requiring chemotherapy, radiation, or current treatment

• Participants with known clotting disorders (self-reported)

  • history of bleeding disorders or personal history of prolonged bleeding from injury,
  • history of blood clots,
  • hemophilia,
  • current use of blood thinner: prescription or daily use of aspirin,
  • Sickle Cell Trait or Disease
• Participants with self-reported dermatological conditions at sensor application sites
• Severe dermatitis,
• Hyperkeratosis,
• Nail fungus
• Participants with severe contact allergies to standard adhesives, latex, silicone or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported)
• Participants with severe allergies to iodine (only applicable if iodine is used)
• Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine),
• Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio <0.4)
• Unwillingness or inability to remove colored nail polish or artificial nails from test digits
• Participants with stretched or dilated piercings at the application site of ear sensors. (Applicable for test groups with M1194A and EX-Alar on ear only.)
• Participant received intravascular dye within the past 48 hours (e.g. Indocyanine green, methylene blue, dyes used in cardiac output monitoring)
• Surgical hardware in pathway of Device Under Test
• Other known health condition, should be considered upon disclosure in health assessment form

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Test Group 1; M1131A (989803205831); M1191T (989803128591); M1191BL (989803144381) for endpoint analysis; M1193A (989803205881)	Device: No Intervention; No Intervention
Test Group 2; M1194A (989803205891); Alar (989803205381); M1191BL (989803144381) as an internal reference only	Device: No Intervention; No Intervention
Test Group 3; EX-Alar on Nasal Ala (Experimental); EX-Alar on Ear (Experimental); M1191BL (989803144381) as an internal reference only	Device: No Intervention; No Intervention
Test Group 4; M1133A (989803205851); EX-M1133A (Experimental); M1196T (989803205911); EX-M1196T (Experimental); M1191BL (989803144381) as an internal reference only (optional)	Device: No Intervention; No Intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
SpO2 Accuracy	Accuracy expressed in ARMS of SpO2 measurements obtained from the SpO2 sensors under test with the Philips Pulse Oximetry technology over the range of 70-100% SaO2, in comparision to SaO2 as ground truth.	May-August 2024

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Non-Disparate Bias	Non-disparate bias and differential mean bias of the SpO2 sensors under test in the SaO2 ranges of 70% ≤ SaO2 ≤ 85% and 85% < SaO2 ≤ 100%.	May-August 2024

Collaborators and Investigators

• Sponsor: Philips Clinical & Medical Affairs Global

Study record dates

Study Major Dates

• Study Start (Actual): May 6, 2024
• Primary Completion (Actual): August 29, 2024
• Study Completion (Actual): August 29, 2024

Study Registration Dates

• First Submitted: June 26, 2024
• First Submitted That Met QC Criteria: June 26, 2024
• First Posted (Actual): July 3, 2024

Study Record Updates

• Last Update Posted (Estimated): September 16, 2025
• Last Update Submitted That Met QC Criteria: September 9, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: CC-300177-FAST 2024

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Study did NOT meet the ACT requirments and will not have results posted.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No